Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
| Descriptor ID |
D015452
|
| MeSH Number(s) |
C04.557.337.428.600.600 C15.604.515.560.600.600 C20.683.515.528.600.600
|
| Concept/Terms |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Precursor B Cell Lymphoblastic Leukemia Lymphoma
- Pre B-ALL
- Pre-B ALL
- Pre B ALL
- Precursor B-Cell Lymphoblastic Leukemia
- Precursor B Cell Lymphoblastic Leukemia
- Precursor B-Cell Lymphoblastic Lymphoma
- Precursor B Cell Lymphoblastic Lymphoma
- Leukemia, Pre-B-Cell
- Leukemia, Pre B Cell
- Leukemias, Pre-B-Cell
- Pre-B-Cell Leukemias
- Pre-B-Cell Leukemia
- Pre B Cell Leukemia
|
Below are MeSH descriptors whose meaning is more general than "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma".
This graph shows the total number of publications written about "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" by people in this website by year, and whether "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 4 | 0 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 5 | 0 | 5 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 5 | 0 | 5 |
| 2020 | 2 | 0 | 2 |
| 2021 | 4 | 0 | 4 |
| 2022 | 1 | 0 | 1 |
| 2023 | 2 | 0 | 2 |
| 2024 | 6 | 1 | 7 |
| 2025 | 8 | 0 | 8 |
| 2026 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" by people in Profiles.
-
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Leukemia. 2026 Oct; 40(10):2181-2190.
-
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. Cancer Res Commun. 2026 07 01; 6(7):1681-1692.
-
Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes. Blood Adv. 2026 06 23; 10(12):4184-4192.
-
Blinatumomab Utilization in Pediatric B-Cell Acute Lymphoblastic Leukemia: Experience From the Mountain West. Pediatr Blood Cancer. 2026 Jul; 73(7):e70383.
-
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 04 23; 147(17):2011-2017.
-
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica. 2026 06 01; 111(6):1999-2010.
-
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era. Hematology Am Soc Hematol Educ Program. 2025 12 05; 2025(1):229-235.
-
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025 11 10; 43(32):3526-3535.
-
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL. Blood Adv. 2025 Sep 09; 9(17):4405-4414.
-
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Bone Marrow Transplant. 2025 11; 60(11):1465-1471.